Advancing Superior Accuracy in Early Lung Cancer Detection Using Selective Metabolic Pathways and Data Enrichment for Enhanced Diagnostic Capabilities Vancouver, British Columbia–(Newsfile Corp. – January 15, 2026) – BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B)…

Celebrating A Year of Extraordinary Achievement Vancouver, British Columbia–(Newsfile Corp. – December 31, 2025) – BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy technologies for early…

Expanding U.S. market access with an experienced technology investor and AI-driven growth strategist Vancouver, British Columbia–(Newsfile Corp. – December 30, 2025) – BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading…

Company engages Standards Council of Canada; targets ISO 15189 accreditation for early 2026 Vancouver, British Columbia–(Newsfile Corp. – December 23, 2025) – BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF), a leading developer of…

Recognition of BioMark Leadership in Early Cancer Detection Validates Commercialization Trajectory of Multimodal Lung Cancer Screening Platform Vancouver, British Columbia–(Newsfile Corp. – December 1, 2025) – BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF)…